Literature DB >> 8794370

Characterization of hepatitis C virus replication in cloned cells obtained from a human T-cell leukemia virus type 1-infected cell line, MT-2.

T Mizutani1, N Kato, S Saito, M Ikeda, K Sugiyama, K Shimotohno.   

Abstract

We recently found that a human T-cell leukemia virus type 1-infected cell line, MT-2, could support the replication of hepatitis C virus (HCV) (N. Kato, T. Nakazawa, T. Mizutani, and K. Shimotohno, Biochem. Biophys. Res. Commun. 206:863-869, 1995). In order to develop a culture system in which HCV replicates more efficiently, we examined the efficiency of HCV replication in cloned MT-2 cell lines by the limiting dilution method. Consequently, we obtained five clones in which intracellular positive-stranded HCV RNA could be detected until at least 21 days postinoculation (p.i.), as opposed to 15 days p.i. in uncloned MT-2 cells. MT-2C, one of the five clones which supported HCV replication up to 30 days p.i., was used for further characterization of HCV replication. Semiquantitative analysis of HCV by PCR revealed that RNA synthesis in infected cells increased after inoculation, reached a maximum level at 4 days p.i., and maintained this level until at least 11 days p.i. The 5' untranslated region of negative-stranded HCV RNA was also detected in the infected cells by two different methods with strand specificity. These results suggest that HCV replicated and multiplied in the MT-2C cells. HCV-infected MT-2C cells that were treated with antibiotics, such as G418 and hygromycin B, sustained HCV RNA for a longer period than did untreated cells. We demonstrated inhibitory effects on HCV replication by an antisense oligonucleotide complementary to the HCV core encoding region and by interferon-alpha. Furthermore, cell-free viral transmission was demonstrated by this culture system. These results suggest that our cell culture system will be useful for studying the mechanism of HCV replication, for screening antiviral agents, and for developing HCV vaccines.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8794370      PMCID: PMC190776     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  39 in total

1.  Marked sequence diversity in the putative envelope proteins of hepatitis C viruses.

Authors:  N Kato; Y Ootsuyama; T Tanaka; M Nakagawa; T Nakazawa; K Muraiso; S Ohkoshi; M Hijikata; K Shimotohno
Journal:  Virus Res       Date:  1992-02       Impact factor: 3.303

2.  Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome.

Authors:  Q L Choo; G Kuo; A J Weiner; L R Overby; D W Bradley; M Houghton
Journal:  Science       Date:  1989-04-21       Impact factor: 47.728

3.  Gene mapping of the putative structural region of the hepatitis C virus genome by in vitro processing analysis.

Authors:  M Hijikata; N Kato; Y Ootsuyama; M Nakagawa; K Shimotohno
Journal:  Proc Natl Acad Sci U S A       Date:  1991-07-01       Impact factor: 11.205

4.  Interferon for non-A, non-B chronic hepatitis. A meta-analysis of randomised clinical trials.

Authors:  F Tinè; S Magrin; A Craxì; L Pagliaro
Journal:  J Hepatol       Date:  1991-09       Impact factor: 25.083

5.  Hypervariable regions in the putative glycoprotein of hepatitis C virus.

Authors:  M Hijikata; N Kato; Y Ootsuyama; M Nakagawa; S Ohkoshi; K Shimotohno
Journal:  Biochem Biophys Res Commun       Date:  1991-02-28       Impact factor: 3.575

6.  Molecular cloning of the human hepatitis C virus genome from Japanese patients with non-A, non-B hepatitis.

Authors:  N Kato; M Hijikata; Y Ootsuyama; M Nakagawa; S Ohkoshi; T Sugimura; K Shimotohno
Journal:  Proc Natl Acad Sci U S A       Date:  1990-12       Impact factor: 11.205

Review 7.  Antisense strategies in cell and developmental biology.

Authors:  A Colman
Journal:  J Cell Sci       Date:  1990-11       Impact factor: 5.285

8.  Structure and organization of the hepatitis C virus genome isolated from human carriers.

Authors:  A Takamizawa; C Mori; I Fuke; S Manabe; S Murakami; J Fujita; E Onishi; T Andoh; I Yoshida; H Okayama
Journal:  J Virol       Date:  1991-03       Impact factor: 5.103

9.  Genetic organization and diversity of the hepatitis C virus.

Authors:  Q L Choo; K H Richman; J H Han; K Berger; C Lee; C Dong; C Gallegos; D Coit; R Medina-Selby; P J Barr
Journal:  Proc Natl Acad Sci U S A       Date:  1991-03-15       Impact factor: 11.205

10.  Hepatic and extrahepatic hepatitis C virus replication in relation to response to interferon therapy.

Authors:  M G Saleh; C J Tibbs; J Koskinas; L M Pereira; A B Bomford; B C Portmann; I G McFarlane; R Williams
Journal:  Hepatology       Date:  1994-12       Impact factor: 17.425

View more
  18 in total

1.  Sequence analysis of the hepatitis C virus genome recovered from serum, liver, and peripheral blood mononuclear cells of infected chimpanzees.

Authors:  Y K Shimizu; H Igarashi; T Kanematu; K Fujiwara; D C Wong; R H Purcell; H Yoshikura
Journal:  J Virol       Date:  1997-08       Impact factor: 5.103

2.  Hepatitis C virus infection of human hepatoma cell line 7721 in vitro.

Authors:  Z Q Song; F Hao; F Min; Q Y Ma; G D Liu
Journal:  World J Gastroenterol       Date:  2001-10       Impact factor: 5.742

3.  Specific interaction of a 25-kilodalton cellular protein, a 40S ribosomal subunit protein, with the internal ribosome entry site of hepatitis C virus genome.

Authors:  S Fukushi; M Okada; T Kageyama; F B Hoshino; K Katayama
Journal:  Virus Genes       Date:  1999       Impact factor: 2.332

4.  Transcriptional activation of the interleukin-2 promoter by hepatitis C virus core protein.

Authors:  A Bergqvist; C M Rice
Journal:  J Virol       Date:  2001-01       Impact factor: 5.103

5.  Cell fusion activity of hepatitis C virus envelope proteins.

Authors:  S Takikawa; K Ishii; H Aizaki; T Suzuki; H Asakura; Y Matsuura; T Miyamura
Journal:  J Virol       Date:  2000-06       Impact factor: 5.103

6.  Hepatitis C virus replication is directly inhibited by IFN-alpha in a full-length binary expression system.

Authors:  R T Chung; W He; A Saquib; A M Contreras; R J Xavier; A Chawla; T C Wang; E V Schmidt
Journal:  Proc Natl Acad Sci U S A       Date:  2001-08-07       Impact factor: 11.205

7.  Nonrandom distribution of hepatitis C virus quasispecies in plasma and peripheral blood mononuclear cell subsets.

Authors:  A M Roque Afonso; J Jiang; F Penin; C Tareau; D Samuel; M A Petit; H Bismuth; E Dussaix; C Féray
Journal:  J Virol       Date:  1999-11       Impact factor: 5.103

Review 8.  The hepatitis C virus persistence: how to evade the immune system?

Authors:  Nicole Pavio; Michael M C Lai
Journal:  J Biosci       Date:  2003-04       Impact factor: 1.826

9.  Inhibition of hepatitis C virus-like particle binding to target cells by antiviral antibodies in acute and chronic hepatitis C.

Authors:  Daniel Steinmann; Heidi Barth; Bettina Gissler; Peter Schürmann; Mohammed I Adah; J Tilman Gerlach; Gerd R Pape; Erik Depla; Dirk Jacobs; Geert Maertens; Arvind H Patel; Geneviève Inchauspé; T Jake Liang; Hubert E Blum; Thomas F Baumert
Journal:  J Virol       Date:  2004-09       Impact factor: 5.103

10.  Specialization of Hepatitis C Virus Envelope Glycoproteins for B Lymphocytes in Chronically Infected Patients.

Authors:  Florian Douam; Louis-Marie Bobay; Guillemette Maurin; Judith Fresquet; Noémie Calland; Carine Maisse; Tony Durand; François-Loïc Cosset; Cyrille Féray; Dimitri Lavillette
Journal:  J Virol       Date:  2015-11-04       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.